Safety and Efficacy of AMT-130 in European Adults With Early Manifest Huntington's Disease

NCT05243017 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

14

Enrollment

INDUSTRY

Sponsor class

Conditions

Huntington Disease

Interventions

GENETIC: intra-striatal rAAV5-miHTT

Sponsor

UniQure Biopharma B.V.